Paper Details

  1. Home
  2. Paper Details

Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol.

Author: BruceIan N, DiamondBetty, FurieRichard A, GordonDavid, GroarkJames, HendersonRobert B, OldhamMary, TakPaul P, TengY K Onno, van VollenhovenRonald F

Clinical Trial ProtocolA plan for conducting a clinical trial. It describes in detail the purpose, design, methodology, and statistical considerations of the trial, ensuring the transparency and consistency of the trial.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Belimumab, an anti-B-lymphocyte-stimulator antibody, and rituximab, a B cell-depleting antibody, are both used in the treatment of systemic lupus erythematosus (SLE). This study proposes that combining these drugs might enhance B cell depletion and therefore improve treatment outcomes for SLE. The researchers aim to compare the efficacy, safety, and tolerability of belimumab combined with rituximab to belimumab alone in patients with SLE.
Paper Details　
Original Abstract of the Article :
Belimumab, an anti-B-lymphocyte-stimulator antibody, is approved for the treatment of active, autoantibody-positive systemic lupus erythematosus (SLE). Rituximab, a B cell-depleting anti-CD20 antibody, remains in the SLE treatment armamentarium despite failed trials in lupus nephritis and extrarenal...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6475247/

データ提供：米国国立医学図書館（NLM）

Belimumab and Rituximab: A Collaborative Journey in Lupus Treatment

Systemic lupus erythematosus (SLE), a complex autoimmune disease, requires a multi-pronged approach to treatment. This study, like a team of camels working together to cross a challenging desert terrain, explores the potential of combining belimumab, an anti-B-lymphocyte-stimulator antibody, with rituximab, a B cell-depleting anti-CD20 antibody, in patients with SLE. The authors designed a phase III, multicenter, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of this combination therapy.

Synergistic Strategies: Harnessing the Power of Combined Therapies

This research investigates the potential benefits of combining belimumab with rituximab for the treatment of SLE. The authors hypothesize that this synergistic approach may lead to enhanced depletion of autoreactive B lymphocytes, potentially improving treatment outcomes.

Navigating the Lupus Landscape: Seeking Comprehensive Care

Living with SLE requires a comprehensive approach to management, including medication, lifestyle modifications, and close monitoring by a rheumatologist. If you are diagnosed with SLE, it's important to work closely with your healthcare team to develop a personalized treatment plan that addresses your specific needs and helps you manage the condition effectively.

Dr.Camel's Conclusion

This study explores the potential of combining belimumab and rituximab for the treatment of SLE, a complex autoimmune disease. The study's findings may offer valuable insights into new therapeutic strategies for this challenging condition. As with navigating a vast desert, seeking guidance from experienced professionals and embracing a multi-faceted approach are essential in managing SLE.

Date :
  1. Date Completed 2020-04-03
  2. Date Revised 2020-04-03
Further Info :

Pubmed ID

30898822

DOI: Digital Object Identifier

PMC6475247

Related Literature

Article Analysis
・Effects of belimumab injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.